Please assess the completion status of the following clinical trial:

Trial Title: β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Admission to the intensive care unit for ≥ 72 hours and expected to stay an additional 48 hours~* IV access for administration of study drug~* Subject (or subject's legal representative) able to give written informed consent~Exclusion Criteria:~* History of hypersensitivity or intolerance to echinocandin antifungals~* Liver function test (ALT, AST (aspartate aminotransferase), and/or total bilirubin) greater than 10 times the upper limits of normal (ULN)~* Pregnant or lactating women~* Treatment with systemic antifungal therapy within the preceding 7 days~* Documented invasive fungal infection at baseline/screening~* Life expectancy less than 2 days or moribund

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): Standard care/empiric therapy group
- 1 (Type: EXPERIMENTAL): Active surveillance/ preemptive therapy group

Based on this trial design, predict the completion outcome and termination type (if applicable).